Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 11/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407150 | 0.90 | MTNR1B (0.47) | MTNR1BHTR2CDRD3HTR1AHSP90AA1 | |
| SCHEMBL28686740 | 0.90 | MTNR1B (0.47) | MTNR1BHTR2CDRD3HTR1AHSP90AA1 | |
| SCHEMBL6405601 | 0.87 | CTSS (0.52) | MTNR1BHTR2CDRD3HTR1ACNR1 | |
| SCHEMBL6404873 | 0.86 | MTNR1B (0.52) | MTNR1BMTNR1AHTR2CDRD3HTR1A | |
| SCHEMBL2261060 | 0.86 | MTNR1B (0.53) | MTNR1BMTNR1ACNR1CNR2 | |
| SCHEMBL22411069 | 0.85 | MTNR1B (0.51) | MTNR1BMTNR1AHTR2CDRD3HTR1A | |
| SCHEMBL2573314 | 0.82 | MTNR1B (0.46) | MTNR1BMTNR1A | |
| SCHEMBL6405961 | 0.82 | HPGD (0.46) | MTNR1BMTNR1A | |
| SCHEMBL27984354 | 0.80 | ALDH1A1 (0.51) | MTNR1BHSP90AA1HSP90AB1ALOX15HSD17B10 | |
| SCHEMBL6405838 | 0.79 | MTNR1B (0.58) | MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | MTNR1B 63/4885MTNR1A 113/4885HTR2C 8/4885 |
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | MTNR1B 329/4885MTNR1A 210/4885HTR2C 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.